drugset / Trial / NCT04041362
the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study assess the safety, tolerability, and efficacy in reducing viral load and proviral DNA of UB-421 administered as an add-on to the ART in ART-experienced viremic HIV-1 subjects.
Timeline
- Start
- 2020-04
- Primary completion
- 2020-12
- Completion
- 2021-03
Outcome
Outcome not reported
Stopped: “The study will not be submitted to authority for IND application.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SEMZUVOLIMAB | Protein / enzyme biologic | 5 mg/kg | Intravenous |